We honor 100 of the leading innovators in pathology and laboratory medicine by celebrating their success at the cutting edge of the field.
David Rimm continues the conversation about the best assay for atezolizumab after a recent response to his original article
Allen M. Gown
Emina Torlakovic and Allen Gown share their disagreements with David Rimm’s comments about an FDA-approved PD-L1 assay for atezolizumab
Not every assay that trials well is practical for implementation in daily practice. How can we tell which ones are, and whose responsibility is it?
A response to David Rimm’s letter that supports the role of PD-L1 testing in improving outcomes for cancer patients.
David L. Rimm
David Rimm challenges the sensitivity and reproducibility of a new assay for PD-L1 detection.
Liquid biopsy can help us appropriately treat patients with anti-PD-L1 immunotherapies, and ddPCR enables ongoing monitoring and adjustment of treatment
An efficient alternative to pap-HPV tests could lie with ddPCR and a ccfDNA assay
Antonia R. Sepulveda
New collaborative guidelines for molecular biomarker testing in colorectal cancer
An examination of domain-specific companion diagnostic testing
An industry pathologist’s perspective on developing a companion diagnostic
Register to access our FREE online portfolio, request the magazine in print and
manage your preferences.